Vitura Health’s first order of MDMA and psilocybin under its joint venture with Canada-based research and development firm PharmAla is expected to be delivered in September as it prepares for the first prescriptions of psychedelics medicine to be written for patients. The JV, called Cortexa, was formed in May following regulator approval for Authorised Prescriber psychiatrists to prescribe the drugs for treatment resistant depression and post-traumatic stress disorder (PTSD). Under the JV, Vitura has exclusive rights to buy and distribute PharmAla’s GMP-manufactured psychedelic products in Australia. The JV has placed its first order of finished products and bulk material for local manufacturing, with the order expected to be delivered to one of Vitura’s distribution centres in September. Final negotiations are also taking place with an Australian contract manufacturer for local production of patient-ready MDMA and psilocybin capsules. In a further development, Cortexa has appointed a medical business development manager to engage with psychiatrists and clinical trial sites for future supply. Meanwhile, a Releaf Group-branded CanView pharmacy app has been rolled out in the four Releaf dispensaries with versions of the app for doctors and patients expected to follow in the coming weeks.
Source: Cannabiz